SecBot SecBot
PRESS-RELEASE ·Filed May 8, 2026

TMCI

Treace Medical Concepts, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The EPS beat is misleading, revenue declined 10% YoY and adjusted EBITDA loss widened. The reaffirmed guidance of 0-5% full-year revenue decline suggests no near-term catalyst for recovery. Monitor Q2 2026 for signs of stabilization; the $115M credit facility provides a liquidity buffer but does not address the fundamental demand headwinds.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$2.01
T+0 close · May 8, 2026 · via day close
Latest settled
+135.82%
T+60 · $4.74
Vs SPY
+130.98%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $2.01entry
  2. T+1 · 6mo ago −3.48%α −3.71% · $1.94
  3. T+5 · 6mo ago +37.81%α +36.35% · $2.77
  4. T+20 · 5mo ago +74.63%α +74.60% · $3.51
  5. T+60 · 4mo ago +135.82%α +130.98% · $4.74

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Treace Medical Concepts reported Q1 2026 revenue of $47.2M (down 10% YoY) and a GAAP net loss of $(0.28)/share, beating consensus EPS estimates of $(0.31) by 51.6%. The company reaffirmed full-year 2026 revenue guidance of $202M-$212M (decline of 5%-0% YoY) and expects continued cash burn reduction, but the top-line decline and widening adjusted EBITDA loss signal ongoing operational headwinds.

Key Financial Metrics

EPS
−$0.28
est −$0.31 · +9.7%
Revenue
$47.2M
est $46.0M · +2.6% · -10.2% YoY
Rating
miss
Guidance
$202M-$212M
maintained
Free Cash Flow
$4.2M
Gross Margin
79.3%

Key Facts

  • Q1 2026 revenue $47.2M, down 10% YoY from $52.6M
  • GAAP net loss $(0.28)/share vs consensus $(0.31), beat on EPS but driven by cost cuts, not revenue growth
  • Adjusted EBITDA loss widened to $(5.5)M from $(3.8)M YoY
  • Full-year 2026 revenue guidance reaffirmed at $202M-$212M (decline of 5%-0% YoY)
  • Cash & marketable securities $51.9M, up $3.5M from Dec 2025; credit facility provides additional $115M
  • Operating cash flow improved to +$7.2M vs +$4.2M in Q1 2025
  • Gross margin slightly compressed to 79.3% from 79.7% YoY
  • Total operating expenses down $2.9M YoY to $54.6M, driven by sales & marketing and R&D cuts

Financial Impact

Revenue decline of $5.4M YoY (10%) with net loss widening by $2.0M; full-year guidance implies continued top-line contraction

revenuenet lossadjusted EBITDAgross margin

Risk Factors

  • Continued revenue decline driven by product mix shift and competitive pressure in bunion surgery market
  • Widening adjusted EBITDA loss signals deteriorating operating leverage
  • Macroeconomic headwinds and soft consumer sentiment may further depress elective bunion surgery volumes
  • Patent litigation costs ($2.3M in Q1) add to cash burn without guarantee of favorable outcomes

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
10% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291003

Track record

11 reports on TMCI

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 20261d ago SC 13G Neutral 4/10 Entry $4.42 to $4.44 Now $4.44 +0.45% ▲ +0.45% +1.47% vs SPY
  2. Nov 16, 20261d ago SC 13G/A Bearish 4/10 Entry $4.42 to $4.44 Now $4.44 −0.45% ▼ −0.45% −1.47% vs SPY
  3. Nov 12, 20266d ago Court Ruling Neutral 4/10 Entry $5.27 to $4.42 Now $4.44 −15.75% ▼ −16.13% −14.22% vs SPY
  4. Nov 6, 202611d ago 8-K Neutral 4/10 Entry $4.03 to $4.78 Now $4.44 +10.17% ▲ +18.61% +16.24% vs SPY
  5. Sep 17, 20268w ago Press Release Neutral 4/10 Entry $4.49 to $4.48 Now $4.44 −1.11% ▼ −0.22% −1.77% vs SPY
  6. Aug 7, 202614w ago 8-K Mixed 6/10 Entry $4.76 to $4.67 Now $4.44 −6.72% ▼ −1.89% −1.86% vs SPY
  7. Jul 13, 202618w ago Court Ruling Bearish 5/10 Entry $4.44 to $4.40 Now $4.44 −0.00% ▲ +0.90% +1.30% vs SPY
  8. May 8, 202627w ago Press Release Bearish 7/10 Viewing Entry $2.01 to $1.94 Now $4.44 −120.90% ▲ +3.48% +3.71% vs SPY
  9. Apr 24, 202629w ago Press Release Neutral 1/10 Entry $1.98 to $1.92 Now $4.44 +124.24% ▼ −3.03% −3.19% vs SPY
  10. Apr 9, 202631w ago 8-K Mixed 6/10 Entry $1.53 to $1.81 Now $4.44 +190.20% ▲ +18.30% +18.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens Thu (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026